Literature DB >> 14684378

Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency.

Jeffrey H Teckman1, Jae-Koo An, Keith Blomenkamp, Bela Schmidt, David Perlmutter.   

Abstract

Homozygous, PIZZ alpha(1)-antitrypsin (alpha(1)-AT) deficiency is associated with chronic liver disease and hepatocellular carcinoma resulting from the toxic effects of mutant alpha(1)-anti-trypsin Z (alpha(1)-ATZ) protein retained in the endoplasmic reticulum (ER) of hepatocytes. However, the exact mechanism(s) by which retention of this aggregated mutant protein leads to cellular injury are still unknown. Previous studies have shown that retention of mutant alpha(1)-ATZ in the ER induces an intense autophagic response in hepatocytes. In this study, we present evidence that the autophagic response induced by ER retention of alpha(1)-ATZ also involves the mitochondria, with specific patterns of both mitochondrial autophagy and mitochondrial injury seen in cell culture models of alpha(1)-AT deficiency, in PiZ transgenic mouse liver, and in liver from alpha(1)-AT-deficient patients. Evidence for a unique pattern of caspase activation was also detected. Administration of cyclosporin A, an inhibitor of mitochondrial permeability transition, to PiZ mice was associated with a reduction in mitochondrial autophagy and injury and reduced mortality during experimental stress. These results provide evidence for the novel concept that mitochondrial damage and caspase activation play a role in the mechanism of liver cell injury in alpha(1)-AT deficiency and suggest the possibility of mechanism-based therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14684378     DOI: 10.1152/ajpgi.00175.2003

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  69 in total

1.  Enhanced mitophagy in Sertoli cells of ethanol-treated rats: morphological evidence and clinical relevance.

Authors:  Nabil Eid; Yuko Ito; Yoshinori Otsuki
Journal:  J Mol Histol       Date:  2011-11-11       Impact factor: 2.611

Review 2.  Novel treatment strategies for liver disease due to α1-antitrypsin deficiency.

Authors:  Nicholas Maurice; David H Perlmutter
Journal:  Clin Transl Sci       Date:  2012-01-10       Impact factor: 4.689

Review 3.  Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease.

Authors:  Sarah K Brode; Simon C Ling; Kenneth R Chapman
Journal:  CMAJ       Date:  2012-07-03       Impact factor: 8.262

Review 4.  Alpha-1 Antitrypsin Deficiency-Mediated Liver Toxicity: Why Do Some Patients Do Poorly? What Do We Know So Far?

Authors:  Marion Bouchecareilh
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

5.  Hepatic progenitor cell proliferation and liver injury in α-1-antitrypsin deficiency.

Authors:  Elizabeth M Brunt; Keith Blomenkamp; Muneeb Ahmed; Faiza Ali; Nancy Marcus; Jeffrey Teckman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-11       Impact factor: 2.839

6.  Mechanisms underlying the cellular clearance of antitrypsin Z: lessons from yeast expression systems.

Authors:  Cristy L Gelling; Jeffrey L Brodsky
Journal:  Proc Am Thorac Soc       Date:  2010-11

7.  Sequestration of mutated alpha1-antitrypsin into inclusion bodies is a cell-protective mechanism to maintain endoplasmic reticulum function.

Authors:  Susana Granell; Giovanna Baldini; Sameer Mohammad; Vanessa Nicolin; Paola Narducci; Brian Storrie; Giulia Baldini
Journal:  Mol Biol Cell       Date:  2007-11-28       Impact factor: 4.138

Review 8.  Protein misfolding and the serpinopathies.

Authors:  Didier Belorgey; Peter Hägglöf; Susanna Karlsson-Li; David A Lomas
Journal:  Prion       Date:  2007-01-06       Impact factor: 3.931

Review 9.  Autophagy in ischemic heart disease.

Authors:  Asa B Gustafsson; Roberta A Gottlieb
Journal:  Circ Res       Date:  2009-01-30       Impact factor: 17.367

Review 10.  Cell death and survival through the endoplasmic reticulum-mitochondrial axis.

Authors:  R Bravo-Sagua; A E Rodriguez; J Kuzmicic; T Gutierrez; C Lopez-Crisosto; C Quiroga; J Díaz-Elizondo; M Chiong; T G Gillette; B A Rothermel; S Lavandero
Journal:  Curr Mol Med       Date:  2013-02       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.